Icotrokinra Shows 2-Year Efficacy in High-Impact Psoriasis Areas
Icotrokinra, an oral peptide targeting the interleukin-23 receptor, demonstrated sustained clinical efficacy through two years in patients with moderate to severe psoriasis affecting high-impact areas such as the scalp, genitals, … Read More